BioVie Inc. is contemplating filing for bankruptcy, as of August 6, 2020. According to company filling, Company said that as it intends to attempt to secure additional required funding primarily through additional equity or debt financings. It may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. If they are unsuccessful in securing funding from any of these sources, they will defer, reduce or eliminate certain planned expenditures in our research protocols. If they do not have sufficient funds to continue operations, they could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment.